635. Efficacy, Pharmacokinetics (PK), and Safety Profile of MEDI3902, an Anti-Pseudomonas aeruginosa Bispecific Human Monoclonal Antibody in Mechanically Ventilated Intensive Care Unit Patients; Results of the Phase 2 EVADE Study Conducted by the Public-Private COMBACTE-MAGNET Consortium in the Innovative Medicines Initiative (IMI) Program

BACKGROUND: Pseudomonas aeruginosa (PA) pneumonia is associated with morbidity and mortality in mechanically ventilated, intensive care unit (MV ICU) patients despite best clinical care. We assessed efficacy, PK, and safety of MEDI3902 in MV ICU subjects in the placebo-controlled, randomized Phase 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Chastre, Jean, François, Bruno, Bourgeois, Marc, Komnos, Apostolos, Ferrer, Ricard, Rahav, Galia, De Schryver, Nicolas, Lepape, Alain, Koksal, Iftihar, Luyt, Charles-Edouard, Garcia, Miguel Sanchez, Torres, Antoni, Holland, Thomas L, Ali, Omar, Shoemaker, Kathryn, Ren, Pin, Ruzin, Alexey, Jiang, Yu, Colbert, Susan, Vandamme, Drieke, Bellamy, Terramika, Reisner, Colin, Dubovsky, Filip, Jafri, Hasan S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776862/
http://dx.doi.org/10.1093/ofid/ofaa439.829

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776862/
http://dx.doi.org/10.1093/ofid/ofaa439.829

Ejemplares similares